天津天津市武清区龙济泌尿男科(天津武清龙济医院男子医院网址) (今日更新中)

The White House said Thursday that new national security adviser John Bolton met with Russian ambassador to the US Anatoly Antonov."Bolton reiterated that it is in the interest of both the United States and Russia to have better relations, but that this will require addressing our concerns regarding Russia's interference in the 2016 election, the reckless use of a chemical weapon in the United Kingdom, and the situations in Ukraine and Syria," the White House statement said.This was the first meeting between the two in their current roles. Bolton officially stepped into the role of White House national security adviser earlier this month after President Donald Trump announced his appointment in March.The meeting came amid heightened tensions between the two nations over Syria, the poisoning in the UK of a former Russian spy and the ongoing special counsel investigation into Russian interference in the 2016 election.Last year, Trump?met with Russian Foreign Minister Sergey Lavrov and Sergey Kisylak, who was Russia's ambassador to the US at the time. Russian state media posted photos of that Oval Office meeting. 1160

The task is painstaking and painful.A searcher is given the name of someone who is missing and an address. The list of names goes on and on.At least 1,300 people are unaccounted for since the Camp Fire erupted 10 days ago, killing 76 people and becoming the deadliest and most destructive fire in California history.Search teams are combing properties where all evidence of life has been wiped out by flames. Many of the searchers are from the devastated areas and have lost their own homes. They are looking for the remains of their neighbors in the ruins."It is overwhelming, I don't have any word to describe it," Butte County Sheriff and Coroner Kory Honea said. "This is unprecedented. No one has had to deal with this magnitude that caused so much destruction and regrettably so much death."The Camp Fire has destroyed more than 9,800 homes and scorched 149,000 acres since it started November 8. It was 55% contained as of early Sunday.Meanwhile, three deaths have been reported in the Woolsey Fire in Southern California, bringing the statewide death toll from the wildfires to 79. 1097

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The Republican National Committee spent more than 0,000 in August to cover some of President Donald Trump's legal fees associated with the federal investigation into Russian meddling in the 2016 election, an RNC official told CNN on Tuesday.The RNC sent 1,250 to Trump's personal attorney Jay Sekulow, via the Constitutional Litigation and Advocacy Group, and 0,000 to John Dowd, the attorney Trump hired in June, the official said.The payments will be disclosed in the RNC's spending report for the month of August, which will be released on Wednesday.Reuters first reported on Tuesday that the RNC was helping Trump with his legal payments associated with the special counsel's investigation. CNN first obtained the total amount of the RNC's spending on Trump's legal bills.The President's legal bills were covered through the RNC's legal defense fund -- not its political coffers -- which the RNC official said was established in 2014 to cover legal fees associated with election-related litigation.The RNC's payments to cover Trump's legal bills come despite the President's claims that his net worth is in excess of billion.The party official said the committee has not yet decided whether it will continue to make payments to cover the President's legal bills.The RNC is just the latest Trump-supporting political group to get involved in making legal payments related to the Russia probe.Last quarter, the Trump campaign spent more than 7,826 on legal fees. Though it's unclear what portion of those fees are going to attorney fees related to the Russia investigation, the campaign has employed attorneys to comply with Russia-related requests and has also made payments to the attorney representing the President's son Donald Trump Jr. in the Russia probe.The Trump campaign spent nearly 0,000 in legal consulting fees -- or about 15.5% of the campaign's expenses between April 1 and June 30, according to the latest Federal Election Commission report. 1992

The situation with Saudi Arabia right now is complicated: A journalist who most recently wrote for "The Washington Post" and who was a supporter of gender equality and freedom of personal expression in the country went missing in October 2018.Jamal Khashoggi was last seen Oct. 2 entering the Saudi Arabia consulate in Istanbul, Turkey, where he had gone to obtain papers for his planned marriage. He was reported missing when no CCTV recorded him leaving the consulate and there were rumors he had been killed and dismembered. 550

来源：资阳报